SG3 Management’s PTC Therapeutics PTCT Stock Holding History

SG3 Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,000	Closed	-$191K	–	134
2022 Q4	$191K	Buy	+5,000	New	+$208K	0.03%	164

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

SG3 Management's PTCT Position: Q1 2023 in Review

SG3 Management sold out of PTC Therapeutics (PTCT) in Q1 2023, closing a stake of 5,000 shares — an estimated $191K sold.

SG3 Management first reported a position in PTCT in Q4 2022 and held it in 1 quarter. The position peaked at $191K in Q4 2022. 203 funds tracked by Wall St. Rank hold PTCT as of Q1 2023.

SG3 Management reported no remaining PTC Therapeutics position as of Q1 2023 after selling out during the quarter.
SG3 Management sold 5,000 PTC Therapeutics shares in Q1 2023, an estimated $191K.
SG3 Management first reported a position in PTC Therapeutics in Q4 2022 and held it in 1 quarter.
SG3 Management's PTC Therapeutics position peaked at $191K in Q4 2022.
203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.